Drugs & Aging

, Volume 27, Issue 6, pp 435–449 | Cite as

Withholding, Discontinuing and Withdrawing Medications in Dementia Patients at the End of Life

A Neglected Problem in the Disadvantaged Dying?
  • Carole ParsonsEmail author
  • Carmel M. Hughes
  • A. Peter Passmore
  • Kate L. Lapane
Current Opinion


Recent years have seen a growing recognition that dementia is a terminal illness and that patients with advanced dementia nearing the end of life do not currently receive adequate palliative care. However, research into palliative care for these patients has thus far been limited. Furthermore, there has been little discussion in the literature regarding medication use in patients with advanced dementia who are nearing the end of life, and discontinuation of medication has not been well studied despite its potential to reduce the burden on the patient and to improve quality of life. There is limited, and sometimes contradictory, evidence available in the literature to guide evidence-based discontinuation of drugs such as acetylcholinesterase inhibitors, antipsychotic agents, HMG-CoA reductase inhibitors (statins), antibacterials, antihypertensives, antihyperglycaemic drugs and anticoagulants. Furthermore, end-of-life care of patients with advanced dementia may be complicated by difficulties in accurately estimating life expectancy, ethical considerations regarding withholding or withdrawing treatment, and the wishes of the patient and/or their family. Significant research must be undertaken in the area of medication discontinuation in patients with advanced dementia nearing the end of life to determine how physicians currently decide whether medications should be discontinued, and also to develop the evidence base and provide guidance on systematic medication discontinuation.


Dementia Palliative Care Memantine Nursing Home Resident Dementia Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



No sources of funding were used to assist in the preparation of this article. Carole Parsons, Carmel Hughes and Kate Lapane have no conflicts of interest that are directly relevant to the content of this article. Professor Passmore has received grants, honoraria and consultancy fees from Pfizer, Eisai, Shire, Janssen and Lundbeck.


  1. 1.
    Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112–7PubMedCrossRefGoogle Scholar
  2. 2.
    Bayer A. Death with dementia: the need for better care. Age Ageing 2006; 35(2): 101–2PubMedCrossRefGoogle Scholar
  3. 3.
    Heron MP, Hoyert DL, Murphy SL, et al. Deaths: final data for 2006. Natl Vital Stat Rep 2009; 57(14): 1–134PubMedGoogle Scholar
  4. 4.
    McCarthy M, Addington-Hall J, Altmann D. The experience of dying with dementia: a retrospective study. Int J Geriatr Psychiatry 1997; 12(3): 404–9PubMedCrossRefGoogle Scholar
  5. 5.
    Sampson EL, Thuné-Boyle I, Kukkastenvehmas R, et al. Palliative care in advanced dementia: a mixed methods approach for the development of a complex intervention. BMC Palliat Care 2008; 7: 8PubMedCrossRefGoogle Scholar
  6. 6.
    Mitchell SL, Kiely DK, Hamel MB. Dying with advanced dementia in the nursing home. Arch Intern Med 2004; 164(3): 321–6PubMedCrossRefGoogle Scholar
  7. 7.
    Sachs GA, Shega JW, Cox-Hayley D. Barriers to excellent end-of-life care for patients with dementia. J Gen Intern Med 2004; 19(10): 1057–63PubMedCrossRefGoogle Scholar
  8. 8.
    Mitchell SL, Morris JN, Park PS, et al. Terminal care for persons with advanced dementia in the nursing home and home care settings. J Palliat Med 2004; 7(6): 808–16PubMedCrossRefGoogle Scholar
  9. 9.
    Miller SC, Mor V, Wu N, et al. Does receipt of hospice care in nursing homes improve the management of pain at the end of life? J Am Geriatr Soc 2002; 50(3): 507–15PubMedCrossRefGoogle Scholar
  10. 10.
    Won A, Lapane K, Gambassi G, et al. Correlates and management of nonmalignant pain in the nursing home. J Am Geriatr Soc 1999; 47(8): 936–42PubMedGoogle Scholar
  11. 11.
    Sampson EL, Ritchie CW, Lai R, et al. A systematic review of the scientific evidence for the efficacy of a palliative care approach in advanced dementia. Int Psychogeriatr 2005; 17(1): 31–40PubMedCrossRefGoogle Scholar
  12. 12.
    Harris D. Forget me not: palliative care for people with dementia. Postgrad Med J 2007; 83: 362–6PubMedCrossRefGoogle Scholar
  13. 13.
    Birch D, Draper J. A critical literature review exploring the challenges of delivering effective palliative care to older people with dementia. J Clin Nurs 2008; 17(9): 1144–63PubMedCrossRefGoogle Scholar
  14. 14.
    Shega JW, Hougham GW, Stocking CB, et al. Patients dying with dementia: experience at the end of life and impact of hospice care. J Pain Symptom Manage 2008; 35: 499–507PubMedCrossRefGoogle Scholar
  15. 15.
    Shega J, Tozer C. Improving the care of people with dementia at the end of life: the role of hospice and the US experience. Dementia 2009; 8(3): 377–89CrossRefGoogle Scholar
  16. 16.
    Mitchell SL, Teno JM, Kiely DK, et al. The clinical course of advanced dementia. N Engl J Med 2009; 361(16): 1529–38PubMedCrossRefGoogle Scholar
  17. 17.
    Morrison RS, Siu AL. Survival in end-stage dementia following acute illness. JAMA 2000; 284(1): 47–52PubMedCrossRefGoogle Scholar
  18. 18.
    Ahronheim JC, Morrison RS, Baskin SA, et al. Treatment of the dying in the acute care hospital: advanced dementia and metastatic cancer. Arch Intern Med 1996; 156(18): 2094–100PubMedCrossRefGoogle Scholar
  19. 19.
    Sachs GA. Dying from dementia. N Engl J Med 2009; 361(16): 1595–6PubMedCrossRefGoogle Scholar
  20. 20.
    Christakis NA, Escarce JJ. Survival of Medicare patients after enrollment in hospice programs. N Engl J Med 1996; 335(3): 172–8PubMedCrossRefGoogle Scholar
  21. 21.
    Miller SC, Gozalo P, Mor V. Hospice enrollment and hospitalization of dying nursing home patients. Am J Med 2001; 111(1): 38–44PubMedCrossRefGoogle Scholar
  22. 22.
    Casarett DJ, Hirschman KB, Henry MR. Does hospice have a role in nursing home care at the end of life? J Am Geriatr Soc 2001; 49(11): 1493–8PubMedCrossRefGoogle Scholar
  23. 23.
    Robinson L, Hughes J, Daley S, et al. End-of-life care and dementia. Rev Clin Gerontol 2005; 15(2): 135–48CrossRefGoogle Scholar
  24. 24.
    Roger KS. A literature review of palliative care, end of life, and dementia. Palliat Support Care 2006; 4(3): 295–303PubMedCrossRefGoogle Scholar
  25. 25.
    Holmes HM. Rational prescribing for patients with a reduced life expectancy. Clin Pharmacol Ther 2009; 85(1): 103–7PubMedCrossRefGoogle Scholar
  26. 26.
    Spinewine A, Schmader KE, Barber N, et al. Appropriate prescribing in elderly people: how well can it be measured and optimised? Lancet 2007; 370(9582): 173–84PubMedCrossRefGoogle Scholar
  27. 27.
    Currow DCB, Stevenson JP, Abernethy AP, et al. Prescribing in palliative care as death approaches. J Am Geriatr Soc 2007; 55(4): 590–5PubMedCrossRefGoogle Scholar
  28. 28.
    Fahlman C, Lynn J, Finch M, et al. Potentially inappropriate medication use by Medicaid Choice beneficiaries in the last year of life. J Palliat Med 2007; 10(3): 686–95PubMedCrossRefGoogle Scholar
  29. 29.
    Holmes HM, Sachs GA, Shega JW, et al. Integrating palliative medicine into the care of persons with advanced dementia: identifying appropriate medication use. J Am Geriatr Soc 2008; 56(7): 1306–11PubMedCrossRefGoogle Scholar
  30. 30.
    Chan VT, Woo BKP, Sewell DD, et al. Reduction of suboptimal prescribing and clinical outcome for dementia patients in a senior behavioral health inpatient unit. Int Psychogeriatr 2009; 21(1): 195–9PubMedCrossRefGoogle Scholar
  31. 31.
    Giron MST, Wang HX, Bernsten C, et al. The appropriateness of drug use in an older nondemented and demented population. J Am Geriatr Soc 2001; 49(3): 277–83PubMedCrossRefGoogle Scholar
  32. 32.
    Bain KTPD, Holmes HM, Beers MH, et al. Discontinuing medications: a novel approach for revising the prescribing stage of the medication-use process. J Am Geriatr Soc 2008; 56(10): 1946–52PubMedCrossRefGoogle Scholar
  33. 33.
    Lee SP, Bain KT, Maio V. Appropriate discontinuation of medications at the end of life: a need to establish consensus criteria. Am J Med Qual 2007; 22(6): 393–4PubMedCrossRefGoogle Scholar
  34. 34.
    Laroche ML, Charmes JP, Bouthier F, et al. Inappropriate medications in the elderly. Clin Pharmacol Ther 2008; 85(1): 94–7PubMedCrossRefGoogle Scholar
  35. 35.
    Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007; 5(4): 345–51PubMedCrossRefGoogle Scholar
  36. 36.
    Koh NY, Koo WH. Polypharmacy in palliative care: can it be reduced? Singapore Med J 2002; 43(6): 279–83PubMedGoogle Scholar
  37. 37.
    Bernard SA, Bruera E. Drug interactions in palliative care. J Clin Oncol 2000; 18(8): 1760–99Google Scholar
  38. 38.
    Blass DM, Black BS, Phillips H, et al. Medication use in nursing home residents with advanced dementia. Int J Geriatr Psychiatry 2008; 23(5): 490–6PubMedCrossRefGoogle Scholar
  39. 39.
    Voisin T, Vellas B. Diagnosis and treatment of patients with severe Alzheimer’s disease. Drugs Aging 2009; 26(2): 135–44PubMedCrossRefGoogle Scholar
  40. 40.
    Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001; 57(4): 613–20PubMedCrossRefGoogle Scholar
  41. 41.
    Winblad B, Kilander L, Eriksson S, et al. Donepezil in patients with severe Alzheimer’s disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006; 367(9516): 1057–65PubMedCrossRefGoogle Scholar
  42. 42.
    Winblad B. Severe Alzheimer’s disease: benefits of donepezil therapy. Int Psychogeriatr 2006; 18(S1): 25–31CrossRefGoogle Scholar
  43. 43.
    Herrmann N, Gauthier S, Lysy PG. Clinical practice guidelines for severe Alzheimer’s disease. Alzheimers Dement 2007; 3: 385–97PubMedCrossRefGoogle Scholar
  44. 44.
    Schmitt FA, Wichems CH. A systematic review of assessment and treatment of moderate to severe Alzheimer’s disease. Prim Care Companion J Clin Psychiatry 2006; 8(3): 158–9PubMedCrossRefGoogle Scholar
  45. 45.
    Black SE, Doody RS, Li H. Donepezil preserves cognition and global function in severe Alzheimer’s disease patients. Neurology 2007; 69: 459–69PubMedCrossRefGoogle Scholar
  46. 46.
    Winblad B. Review: Donepezil in severe Alzheimer’s disease. Am J Alzheimers Dis Other Demen 2009; 24(3): 185–92PubMedCrossRefGoogle Scholar
  47. 47.
    Herrmann N, Gill SS, Bell CM, et al. A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc 2007; 55(10): 1517–23PubMedCrossRefGoogle Scholar
  48. 48.
    Rodda J, Walker Z. Ten years of cholinesterase inhibitors. Int J Geriatr Psychiatry 2009; 24(5): 437–42PubMedCrossRefGoogle Scholar
  49. 49.
    Seltzer B. Is long-term treatment of Alzheimer’s disease with cholinesterase inhibitor therapy justified? Drugs Aging 2007; 24(11): 881–90PubMedCrossRefGoogle Scholar
  50. 50.
    Weschules DJ, Maxwell TL, Shega JW. Acetylcholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use among hospice enrollees with a primary diagnosis of dementia. J Palliat Med 2008; 11(5): 738–45PubMedCrossRefGoogle Scholar
  51. 51.
    Herrmann N, Gauthier S. Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease. Can Med Assoc J 2008; 179(12): 1279–87CrossRefGoogle Scholar
  52. 52.
    Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev 2006: Jan 25; (1): CD005593Google Scholar
  53. 53.
    Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001; 58(3): 427–33PubMedCrossRefGoogle Scholar
  54. 54.
    Daiello LA, Ott BR, Lapane K, et al. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. Am J Geriatr Pharmacother 2009; 7(2): 74–83PubMedCrossRefGoogle Scholar
  55. 55.
    Singh S, Dudley C. Discontinuation syndrome following donepezil cessation. Int J Geriatr Psychiatry 2003; 18(4): 282–4PubMedCrossRefGoogle Scholar
  56. 56.
    Okazaki T, Furukawa K, Kubo H, et al. Paralytic ileus after discontinuation of cholinesterase inhibitor. J Am Geriatr Soc 2006; 54(10): 1620–1PubMedCrossRefGoogle Scholar
  57. 57.
    Simpson S, Beavis D, Leddy A, et al. Naturalistic audit of NICE criteria for the use of cholinesterase inhibitors. Psychiatr Bull R Coll Psychiatr 2005; 29(11): 410–2CrossRefGoogle Scholar
  58. 58.
    Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63(2): 214–9PubMedCrossRefGoogle Scholar
  59. 59.
    Shega JW, Ellner L, Lau DT et al. Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors. J Palliat Med 2009; 12(9): 779–83PubMedCrossRefGoogle Scholar
  60. 60.
    Sorensen L, Foldspang A, Gulmann NC, et al. Determinants for the use of psychotropics among nursing home residents. Int J Geriatr Psychiatry 2001; 16(2): 147–54PubMedCrossRefGoogle Scholar
  61. 61.
    Briesacher BA, Limcangco MR, Simoni-Wastila L, et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med 2005; 165(11): 1280–5PubMedCrossRefGoogle Scholar
  62. 62.
    Ballard C, Lana MM, Theodoulou M, et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med 2008; 5(4): e76PubMedCrossRefGoogle Scholar
  63. 63.
    Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8(2): 151–7PubMedCrossRefGoogle Scholar
  64. 64.
    O’Brien J. Antipsychotics for people with dementia [editorial]. BMJ 2008; 337(92): a602PubMedCrossRefGoogle Scholar
  65. 65.
    Rochon PA, Stukel TA, Bronskill SE, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med 2007; 167(7): 676–83PubMedCrossRefGoogle Scholar
  66. 66.
    Nijk RM, Zuidema SU, Koopmans RTCM. Prevalence and correlates of psychotropic drug use in Dutch nursing-home patients with dementia. Int Psychogeriatr 2009; 21(3): 485–93PubMedCrossRefGoogle Scholar
  67. 67.
    Lövheim H, Sandman PO, Kallin K, et al. Relationship between antipsychotic drug use and behavioral and psychological symptoms of dementia in old people with cognitive impairment living in geriatric care. Int Psychogeriatr 2006; 18(4): 713–26PubMedCrossRefGoogle Scholar
  68. 68.
    Selbaek G, Kirkevold O, Engedal K. The prevalence of psychiatric symptoms and behavioural disturbances and the use of psychotropic drugs in Norwegian nursing homes. Int J Geriatr Psychiatry 2007; 22(9): 843–9PubMedCrossRefGoogle Scholar
  69. 69.
    Pitkala KH, Laurila JV, Strandberg TE, et al. Behavioral symptoms and the administration of psychotropic drugs to aged patients with dementia in nursing homes and in acute geriatric wards. Int Psychogeriatr 2004; 16(1): 61–74PubMedCrossRefGoogle Scholar
  70. 70.
    Margallo-Lana M, Swann A, O’Brien J, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 2001; 16(1): 39–44PubMedCrossRefGoogle Scholar
  71. 71.
    Cohen-Mansfield J, Lipson S, Werner P, et al. Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study. Arch Intern Med 1999; 159(15): 1733–40PubMedCrossRefGoogle Scholar
  72. 72.
    Ballard CG, Thomas A, Fossey J, et al. A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome. J Clin Psychiatry 2004; 65(1): 114–9PubMedCrossRefGoogle Scholar
  73. 73.
    Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med 2006; 355(15): 1525–38PubMedCrossRefGoogle Scholar
  74. 74.
    Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer’s disease: randomised double blind placebo controlled trial. BMJ 2005; 330(7496): 874PubMedCrossRefGoogle Scholar
  75. 75.
    Ruths S, Straand J, Nygaard HA, et al. Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study. The Bergen District Nursing Home Study (BEDNURS). Int J Geriatr Psychiatry 2008; 23(9): 889–95PubMedCrossRefGoogle Scholar
  76. 76.
    Bridges-Parlet S, Knopman D, Steffes S. Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment-controlled pilot study. J Geriatr Psychiatry Neurol 1997; 10(3): 119–26PubMedGoogle Scholar
  77. 77.
    van Reekum R, Clarke D, Conn D, et al. A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia. Int Psychogeriatr 2005; 14(2): 197–210CrossRefGoogle Scholar
  78. 78.
    Ruths S, Straand J, Nygaard HA, et al. Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study the Bergen District Nursing Home Study. J Am Geriatr Soc 2004; 52(10): 1737–43PubMedCrossRefGoogle Scholar
  79. 79.
    Gill SS, Bronskill SE, Normand SLT, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146(11): 775–86PubMedGoogle Scholar
  80. 80.
    Mortimer AM, Shepherd CJ, Rymer M, et al. Primary care use of antipsychotic drugs: an audit and intervention study. Ann Gen Psychiatry 2005; 4: 18PubMedCrossRefGoogle Scholar
  81. 81.
    Vollrath AM, Sinclair C, Hallenbeck J. Discontinuing cardiovascular medications at the end of life: lipidlowering agents. J Palliat Med 2005; 8(4): 876–81PubMedCrossRefGoogle Scholar
  82. 82.
    Silveira MJ, Kazanis AS, Shevrin MP. Statins in the last six months of life: a recognizable, life-limiting condition does not decrease their use. J Palliat Med 2008; 11(5): 685–93PubMedCrossRefGoogle Scholar
  83. 83.
    Chen JH, Lamberg JL, Chen YC, et al. Occurrence and treatment of suspected pneumonia in long-term care residents dying with advanced dementia. J Am Geriatr Soc 2006; 54(2): 290–5PubMedCrossRefGoogle Scholar
  84. 84.
    van der Steen JT, Kruse RL, Ooms ME, et al. Treatment of nursing home residents with dementia and lower respiratory tract infection in the United States and the Netherlands: an ocean apart. J Am Geriatr Soc 2004; 52(5): 691–9PubMedCrossRefGoogle Scholar
  85. 85.
    Hughes JC, Jolley D, Jordan A, et al. Palliative care in dementia: issues and evidence. Adv Psychiatr Treat 2007; 13: 251–60CrossRefGoogle Scholar
  86. 86.
    van der Steen JT, Ooms ME, van der Wal G, et al. Pneumonia: the demented patient’s best friend? Discomfort after starting or withholding antibiotic treatment. J Am Geriatr Soc 2002; 50(10): 1681–8PubMedCrossRefGoogle Scholar
  87. 87.
    Morrison RS, Ahronheim JC, Morrison GR, et al. Pain and discomfort associated with common hospital procedures and experiences. J Pain Symptom Manage 1998; 15(2): 91–101PubMedGoogle Scholar
  88. 88.
    Luchins DJ, Hanrahan P. What is appropriate health care for end-stage dementia? J Am Geriatr Soc 1993; 41(1): 25–30PubMedGoogle Scholar
  89. 89.
    Hurley AC, Volicer BJ, Volicer L. Effect of fever-management strategy on the progression of dementia of the Alzheimer type. Alzheimer Dis Assoc Disord 1996; 10(1): 5–10PubMedGoogle Scholar
  90. 90.
    Fabiszewski K, Volicer B, Volicer L. Effect of antibiotic treatment on outcome of fevers in institutionalized Alzheimer patients. JAMA 1990; 263(23): 3168–72PubMedCrossRefGoogle Scholar
  91. 91.
    Hurley AC, Volicer B, Mahoney MA, et al. Palliative fever management in Alzheimer patients: quality plus fiscal responsibility. Adv Nurs Sci 1993; 16: 21–32Google Scholar
  92. 92.
    Volicer L, Collard A, Hurley A, et al. Impact of special care unit for patients with advanced Alzheimer’s disease on patients’ discomfort and costs. J Am Geriatr Soc 1994; 42(6): 597–603PubMedGoogle Scholar
  93. 93.
    Volicer L, Rheaume Y, Brown J, et al. Hospice approach to the treatment of patients with advanced dementia of the Alzheimer type. JAMA 1986; 256(16): 2210–3PubMedCrossRefGoogle Scholar
  94. 94.
    Evers MM, Purohit D, Perl D, et al. Palliative and aggressive end-of-life care for patients with dementia. Psychiatr Serv 2002; 53(5): 609–13PubMedCrossRefGoogle Scholar
  95. 95.
    van der Steen JT, Ooms ME, Adèr HJ, et al. Withholding antibiotic treatment in pneumonia patients with dementia: a quantitative observational study. Arch Intern Med 2002; 162(15): 1753–60PubMedCrossRefGoogle Scholar
  96. 96.
    D’Agata E, Mitchell SL. Patterns of antimicrobial use among nursing home residents with advanced dementia. Arch Intern Med 2008; 168(4): 357–62PubMedCrossRefGoogle Scholar
  97. 97.
    Mehr DR, van der Steen JT, Kruse RL, et al. Lower respiratory infections in nursing home residents with dementia: a tale of two countries. Gerontologist 2003; 43Suppl. 2: 85–93PubMedCrossRefGoogle Scholar
  98. 98.
    van der Steen JT, Helton MR, Ribbe MW. Prognosis is important in decisionmaking in Dutch nursing home patients with dementia and pneumonia. Int J Geriatr Psychiatry 2009; 24: 933–6PubMedCrossRefGoogle Scholar
  99. 99.
    Ford-Dunn S, Smith A, Quin J. Management of diabetes during the last days of life: attitudes of consultant diabetologists and consultant palliative care physicians in the UK. Palliat Med 2006; 20(3): 197–203PubMedCrossRefGoogle Scholar
  100. 100.
    Ford-Dunn S, Smith A, Quin J. Blood glucose levels in diabetic patients during the terminal phase: is continuation of treatment necessary? [abstract]. Palliat Med 2004; 18: 161Google Scholar
  101. 101.
    Spiess JL. Can I stop the warfarin? A review of the risks and benefits of discontinuing anticoagulation. J Palliat Med 2009; 12(1): 83–7PubMedCrossRefGoogle Scholar
  102. 102.
    Björkman M, Sorva A, Risteli J et al. Vitamin D supplementation has minor effects on parathyroid hormone and bone turnover markers in vitamin D-deficient bedridden older patients. Age Ageing 2008; 37: 25–31PubMedCrossRefGoogle Scholar
  103. 103.
    Derse AR. Limitation of treatment at the end-of-life: withholding and withdrawal. Clin Geriatr Med 2005; 21(1): 223–38PubMedCrossRefGoogle Scholar
  104. 104.
    Rurup ML, Onwuteaka-Philipsen BD, Pasman HRW, et al. Attitudes of physicians, nurses and relatives towards end-of-life decisions concerning nursing home patients with dementia. Patient Educ Couns 2006; 61(3): 372–80PubMedCrossRefGoogle Scholar
  105. 105.
    Maust DT, Blass DM, Black BS, et al. Treatment decisions regarding hospitalization and surgery for nursing home residents with advanced dementia: the CareAD study. Int Psychogeriatr 2008; 20(2): 406–18PubMedCrossRefGoogle Scholar
  106. 106.
    Mitchell SL, Kiely DK, Hamel MB, et al. Estimating prognosis for nursing home residents with advanced dementia. JAMA 2004; 291(22): 2734–40PubMedCrossRefGoogle Scholar
  107. 107.
    Volicer BJ, Hurley A, Fabiszewski KJ, et al. Predicting short-term survival for patients with advanced Alzheimer’s disease. J Am Geriatr Soc 1993; 41(5): 535–40PubMedGoogle Scholar
  108. 108.
    Hanrahan P, Luchins DJ. Access to hospice programs in end-stage dementia: a national survey of hospice programs. J Am Geriatr Soc 1995; 43(1): 56–9PubMedGoogle Scholar
  109. 109.
    Luchins DJ, Hanrahan P, Murphy K. Criteria for enrolling dementia patients in hospice. J Am Geriatr Soc 1997; 45(9): 1054–9PubMedGoogle Scholar
  110. 110.
    Volicer L. Hospice care for dementia patients. J Am Geriatr Soc 1997; 45(9): 1147–9PubMedGoogle Scholar
  111. 111.
    Murtagh FE, Preston M, Higginson I. Patterns of dying: palliative care for non-malignant disease. Clin Med 2004; 4(1): 39–44PubMedCrossRefGoogle Scholar
  112. 112.
    Holmes HM, Hayley DC, Alexander GC, et al. Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006; 166(6): 605–9PubMedCrossRefGoogle Scholar
  113. 113.
    Phillips LS, Branch WT, Cook CB, et al. Clinical inertia. Arch Intern Med 2001; 135(9): 825–34Google Scholar
  114. 114.
    Caron CD, Griffith J, Arcand M. End-of-life decision making in dementia: the perspective of family caregivers. Dementia 2005; 4(1): 113–36CrossRefGoogle Scholar
  115. 115.
    Low J, Chan D, Hung W, et al. Treatment of recurrent aspiration pneumonia in end-stage dementia: preferences and choices of a group of elderly nursing home residents. Intern Med J 2003; 33(8): 345–9PubMedCrossRefGoogle Scholar
  116. 116.
    Helton MR, van der Steen JT, Daaleman TP, et al. A cross-cultural study of physician treatment decisions for demented nursing home patients who develop pneumonia. Ann Fam Med 2006; 4(3): 221–7PubMedCrossRefGoogle Scholar
  117. 117.
    Seale C. End-of-life decisions in the UK involving medical practitioners. Palliat Med 2009; 23(3): 198–204PubMedCrossRefGoogle Scholar
  118. 118.
    Nakanishi M, Honda T. Processes of decision making and end-of-life care for patients with dementia in group homes in Japan. Arch Gerontol Geriatr 2009; 48(3): 296–9PubMedCrossRefGoogle Scholar
  119. 119.
    Onwuteaka-Philipsen BD, Fisher S, Cartwright C, et al. End-of-life decision making in Europe and Australia: a physician survey. Arch Intern Med 2006; 166(8): 921–9PubMedCrossRefGoogle Scholar
  120. 120.
    Hinkka H, Kosunen E, Lammi U, et al. Decision making in terminal care: a survey of Finnish doctors’ treatment decisions in end-of-life scenarios involving a terminal cancer and a terminal dementia patient. Palliat Med 2002; 16(3): 195–204PubMedCrossRefGoogle Scholar
  121. 121.
    Eisemann M, Richter J, Bauer B, et al. Physicians’ decisionmaking in incompetent elderly patients: a comparative study between Austria, Germany (East, West), and Sweden. Int Psychogeriatr 1999; 11(3): 313–24PubMedCrossRefGoogle Scholar
  122. 122.
    Richter J, Eisemann M, Zgonnikova E. Doctors’ authoritarianism in end-of-life treatment decisions: a comparison between Russia, Sweden and Germany. J Med Ethics 2001; 27(3): 186–91PubMedCrossRefGoogle Scholar
  123. 123.
    Richter J, Eisemann MR, Zgonnikova E. Doctors’ attitudes and end-of-life decisions in the elderly: a comparative study between Sweden, Germany and Russia. Arch Gerontol Geriatr 2002; 34(2): 107–15PubMedCrossRefGoogle Scholar
  124. 124.
    Thompson T, Barbour R, Schwartz L. Adherence to advance directives in critical care decision making: vignette study. BMJ 2003; 327(7422): 11CrossRefGoogle Scholar
  125. 125.
    Farber NJ, Simpson P, Salam T, et al. Physicians’ decisions to withhold and withdraw life-sustaining treatment. Arch Intern Med 2006; 166(5): 560–4PubMedCrossRefGoogle Scholar
  126. 126.
    van der Steen JT, Ooms ME, van der Wal G, et al. Withholding or starting antibiotic treatment in patients with dementia and pneumonia: prediction of mortality with physicians’ judgment of illness severity and with specific prognostic models. Med Decis Making 2005; 25(2): 210–21PubMedCrossRefGoogle Scholar
  127. 127.
    van der Steen JT, Muller MT, Ooms ME, et al. Decisions to treat or not to treat pneumonia in demented psychogeriatric nursing home patients: development of a guideline. J Med Ethics 2000; 26(2): 114–20PubMedCrossRefGoogle Scholar
  128. 128.
    Aoun SM, Kristjanson LJ. Challenging the framework for evidence in palliative care research. Palliat Med 2005; 19(6): 461–5PubMedCrossRefGoogle Scholar
  129. 129.
    Kaasa S, Hjermstad MJ, Loge JH. Methodological and structural challenges in palliative care research: how have we fared in the last decades? Palliat Med 2006; 20(8): 727–34PubMedCrossRefGoogle Scholar
  130. 130.
    Flemming K, Adamson J, Atkin K. Improving the effectiveness of interventions in palliative care: the potential role of qualitative research in enhancing evidence from randomized controlled trials. Palliat Med 2008; 22(2): 123–31PubMedCrossRefGoogle Scholar
  131. 131.
    Wee B, Hadley G, Derry S. How useful are systematic reviews for informing palliative care practice? Survey of 25 Cochrane systematic reviews. BMC Palliat Care 2008; 7: 13PubMedCrossRefGoogle Scholar
  132. 132.
    Mitchell SL. A 93-year-old man with advanced dementia and eating problems. JAMA 2007; 298(21): 2527–36PubMedCrossRefGoogle Scholar
  133. 133.
    Gastmans C, De Lepeleire J. Living to the bitter end? A personalist approach to euthanasia in persons with severe dementia. Bioethics 2010 Feb; 24(2): 78–86PubMedCrossRefGoogle Scholar
  134. 134.
    Black BS, Fogarty LA, Phillips H, et al. Surrogate decision makers’ understanding of dementia patients’ prior wishes for end-of-life care. J Aging Health 2009; 21(4): 627–50PubMedCrossRefGoogle Scholar
  135. 135.
    Caron CD, Griffith J, Arcand M. Decision making at the end of life in dementia: how family caregivers perceive their interactions with health care providers in long-term-care settings. J Appl Gerontol 2005; 24(3): 231–47CrossRefGoogle Scholar
  136. 136.
    Hirschman KB, Kapo JM, Karlawish JHT. Identifying the factors that facilitate or hinder advance planning by persons with dementia. Alzheimer Dis Assoc Disord 2008; 22(3): 293–8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Carole Parsons
    • 1
    Email author
  • Carmel M. Hughes
    • 1
  • A. Peter Passmore
    • 2
  • Kate L. Lapane
    • 3
  1. 1.Clinical and Practice Research Group, School of PharmacyQueen’s University BelfastBelfastNorthern Ireland
  2. 2.Department of Geriatric Medicine, School of Medicine, Dentistry and Biomedical SciencesQueen’s University BelfastBelfastNorthern Ireland
  3. 3.Department of Epidemiology and Community HealthVirginia Commonwealth UniversityRichmondUSA

Personalised recommendations